Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Alexion Pharmaceuticals, Inc.
  6. Summary
    ALXN   US0153511094

ALEXION PHARMACEUTICALS, INC.

(ALXN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
05/11/2021 05/12/2021 05/13/2021 05/14/2021 05/17/2021 Date
171.41(c) 171.99(c) 173.33(c) 173.49(c) 174.75(c) Last
2 370 572 2 051 693 1 340 506 1 417 833 1 275 744 Volume
-0.23% +0.34% +0.78% +0.09% +0.73% Change
More quotes
Financials (USD)
Sales 2021 6 650 M - -
Net income 2021 2 498 M - -
Net cash position 2021 2 566 M - -
P/E ratio 2021 15,6x
Yield 2021 -
Sales 2022 7 161 M - -
Net income 2022 2 753 M - -
Net cash position 2022 4 395 M - -
P/E ratio 2022 13,9x
Yield 2022 -
Capitalization 38 623 M 38 623 M -
EV / Sales 2021 5,42x
EV / Sales 2022 4,78x
Nbr of Employees 3 837
Free-Float 90,8%
More Financials
Company
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s marketed products include SOLIRIS (eculizumab), Strensiq (asfotase alfa), Kanuma (sebelipase alfa), ULTOMIRIS, Andexxa and Ondexxya. The Company’s clinical development programs include ALXN1210, ALXN1810, ALXN1720, ALXN1830, ALXN1840 and ABY-039. The... 
Read more
Sector
Pharmaceuticals
Calendar
07/29Earnings Release
More about the company
Notations Surperformance© of Alexion Pharmaceuticals, Inc.
Trading Rating : Investor Rating :
More Ratings
All news about ALEXION PHARMACEUTICALS, INC.
05/13ALEXION PHARMACEUTICALS  : Submission of Matters to a Vote of Security Holders, ..
AQ
05/12ALEXION PHARMACEUTICALS  : Caelum and Alexion Announce Upcoming CAEL-101 Data Pr..
BU
05/12ALEXION PHARMACEUTICALS  : Announces Upcoming Data Presentations at the 26th Eur..
BU
05/11ALEXION PHARMACEUTICALS, INC.  : Submission of Matters to a Vote of Security Hol..
AQ
05/11ASTRAZENECA  : Shareholders OK Acquisition of Alexion Pharmaceuticals
MT
05/11STREET COLOR : AstraZeneca Shareholders Vote in Favor of Alexion Pharmaceutical ..
MT
05/11ALEXION PHARMACEUTICALS  : Shareholders Approve Acquisition by AstraZeneca
BU
05/10ALEXION PHARMACEUTICALS  : Shareholders Approve Acquisition by AstraZeneca (Form..
PU
05/10PASCAL SORIOT : AstraZeneca plan to beef up CEO Soriot's pay packet faces scruti..
RE
05/05ALEXION PHARMACEUTICALS  : Oppenheimer Upgrades Alexion Pharmaceuticals to Outpe..
MT
05/04ALEXION PHARMACEUTICALS, INC.  : Other Events (form 8-K)
AQ
05/03ALEXION PHARMACEUTICALS  : SVB Leerink Adjusts Alexion Pharmaceuticals PT to $17..
MT
05/03EARNINGS REACTION HISTORY : Alexion Pharmaceuticals, 16.7% Follow-Through Indica..
MT
04/30ALEXION : Q1 Earnings Snapshot
AQ
04/30ALEXION PHARMACEUTICALS  : Q1 Earnings, Revenue Climb
MT
More news
News in other languages on ALEXION PHARMACEUTICALS, INC.
05/11ASTRAZENECA : l'AG valide le rachat d'Alexion, rechigne face aux rémunérations
05/11ASTRAZENECA  : les actionnaires approuvent le rachat d'Alexion
05/06FINANZA  : la biotech italiana Genenta Science verso il Nasdaq (MF)
04/30ASTRAZENECA  : ingresa 275 millones de dólares por la vacuna anti-COVID
04/30Astrazeneca steigert Gewinn deutlich und bekräftigt Ausblick
More news
Analyst Recommendations on ALEXION PHARMACEUTICALS, INC.
More recommendations
Analysis
AstraZeneca plan to beef up CEO Soriot's pay packet faces scrutiny at AGM
Chart ALEXION PHARMACEUTICALS, INC.
Duration : Period :
Alexion Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ALEXION PHARMACEUTICALS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 19
Average target price 174,88 $
Last Close Price 174,75 $
Spread / Highest target 17,3%
Spread / Average Target 0,07%
Spread / Lowest Target -19,9%
EPS Revisions
Managers and Directors
NameTitle
Ludwig N. Hantson Chief Executive Officer & Director
Aradhana Sarin Chief Financial Officer & Executive Vice President
David Richard Brennan Chairman
John J. Orloff Executive VP, Head-Research & Development
George Llado Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
ALEXION PHARMACEUTICALS, INC.11.04%38 345
CSL LIMITED-2.33%98 249
WUXI BIOLOGICS (CAYMAN) INC.4.96%57 290
SAMSUNG BIOLOGICS CO.,LTD.14.77%55 625
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.50.80%53 688
BIOGEN INC.14.44%42 187